BioCentury
ARTICLE | Finance

Milestone's options

What cardio play Milestone plans to do with its upsized $55M series C round.

August 4, 2017 10:16 PM UTC

Milestone Pharmaceuticals Inc. turned positive Phase II data for etripamil into an upsized $55 million series C round, which will give the cardiovascular company leeway to expand its core program or in-license a second cardio asset.

Milestone raised the round’s first tranche on Aug. 1. Novo Holdings A/S led the round with participation from fellow new investors Forbion Capital Partners and Tekla Capital Management and existing investors Domain Associates, Fonds de solidarité FTQ, BDC Capital, Pappas Capital and GO Capital. ...

BCIQ Company Profiles

Milestone Pharmaceuticals Inc.

BCIQ Target Profiles

Calcium channel